COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Tobacco Constituents and Biomarkers.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04090606
Recruitment Status : Active, not recruiting
First Posted : September 16, 2019
Last Update Posted : February 5, 2020
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota

Brief Summary:
This proposal addresses several research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products as mandated by the Family Smoking Prevention and Tobacco Control Act. Scientific evidence supports the important role of tobacco and cigarette smoke carcinogens in the development of cancers associated with cigarette smoking. Regulation of the levels of harmful constituents in cigarette smoke is one of the tobacco control strategies that now can be employed by the FDA and may serve to reduce tobacco carcinogen exposures in those smokers who are unable or unwilling to quit smoking. Such regulation will require a valid and robust approach to the assessment of comparative toxicity and carcinogenicity among various cigarette brands. This proposal will help develop a testing approach that can produce meaningful predictions of changes in human exposure due to changes in constituent levels in cigarette smoke, and hence serve as a reliable measure for product regulation. Thus, the proposed research will generate findings and data that are directly relevant to inform the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. The human trial deals with Aims 2 and 3 of this study.

Condition or disease Intervention/treatment
Smoking Other: FTC Method Smoking Regimen Other: Massachusetts Method Smoking Regimen Other: Health Canada Intense Smoking Regimen

Layout table for study information
Study Type : Observational
Actual Enrollment : 65 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Constituent Yields and Biomarkers of Exposure for Tobacco Product Regulation
Actual Study Start Date : December 2013
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : January 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Smoking

Group/Cohort Intervention/treatment
FTC Method Other: FTC Method Smoking Regimen
cigarettes are smoked by drawing 35 mL puff volumes over 2 s, with 60 s interval between puffs and no blocking of filter ventilation holes

Massachusetts Method Other: Massachusetts Method Smoking Regimen
45-mL puffs drawn over 2 s, with 30 s interval between puffs and 50% blocking of filter ventilation holes

Health Canada Intense Method Other: Health Canada Intense Smoking Regimen
55-mL puff volumes of 2-s duration, with 30 s interval between puffs and 100% blocking of filter ventilation holes

Primary Outcome Measures :
  1. The extent to which differences in smoke yields of NNN and NNK per mg nicotine are predictive of differences in smokers' exposure to these carcinogens (human trial) [ Time Frame: 1 Year ]
    Correlation between urinary total NNN and total NNAL (with and without normalization for total nicotine intake) in smokers and the machine-measured yields of NNN and NNK (per mg nicotine and per cigarette) in cigarettes smoked by these individuals. The relationship will be investigated for the machine-measured yields generated by 3 different smoking regimens.

  2. The extent to which NNN and NNK per mg nicotine levels in spent cigarette filters are predictive of differences in smokers' exposure to these carcinogens (human trial) [ Time Frame: 1 Year ]
    Correlation, for each smoker, between the TSNA per mg nicotine content in their spent cigarette filters with the levels of total NNN and total NNAL per nicotine equivalents in their urine

Secondary Outcome Measures :
  1. Individual factors affecting TSNA per mg nicotine and exposures in smokers (human trial) [ Time Frame: 1 Year ]
    Correlation (if any) of individual factors and the relationship between the machine-measured TSNA per mg nicotine and exposures in smokers.

  2. Relationship between 1-HOP and TSNA per mg Nicotine [ Time Frame: 1 Year ]
    Correlation between urinary biomarker of polycyclic aromatic hydrocarbon exposure (1-HOP) and TSNA per mg nicotine yields in cigarette smoke.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Adult smokers from Minneapolis-St. Paul metro area

Inclusion Criteria:

  • Male or female adult smokers 18-65 years of age, who smoke at least 7 cigarettes per day (to assure that biomarker levels are above the limit of quantitation) and do not have plans to quit smoking in the next month;
  • Smoked the same brand for >80% of their cigarettes over the course of at least 1 year, and smoked not more than 20 cigarettes (1 pack) of a different brand within two weeks prior to the eligibility screening;
  • Not using any other nicotine or tobacco product;
  • Subjects who are not taking any medications that affect relevant metabolic enzymes;
  • Women who are not pregnant or nursing;
  • Subjects have provided written informed consent to participate in the study (adolescents under the age of 18 will be excluded because this project involves use of tobacco products).

Exclusion Criteria:

  • Significant immune system disorders, respiratory diseases, kidney or liver diseases or any other medical disorders that may affect biomarker data;
  • Current or recent alcohol or drug abuse problems (to ensure alcohol and drug use does not affect biomarkers of exposure and to maximize retention);
  • Regular tobacco use (e.g., greater than weekly) other than cigarettes;
  • Currently using nicotine replacement or other tobacco cessation products (to minimize confounding effects of another product);
  • Pregnant or breastfeeding (due to toxic effects from tobacco products)
  • Report smoking more than 1 pack (20 cigarettes) of a non-usual brand cigarette in the past two weeks * Participants who report smoking 2 or more non-usual brand cigarettes the day before the clinic visit will be ineligible
Layout table for additonal information
Responsible Party: Masonic Cancer Center, University of Minnesota Identifier: NCT04090606    
Other Study ID Numbers: 2013NTLS115
First Posted: September 16, 2019    Key Record Dates
Last Update Posted: February 5, 2020
Last Verified: February 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No